CoLucid is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals. Lasmiditan is a new chemical entity designed to deliver efficacy without the vasoconstrictor effects of previous therapies. It is a member of a novel drug class called "ditans" which penetrates the central nervous system and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. The initial development program for lasmiditan will address the major unmet need of migraine patients with risk factors for cardiovascular disease and those with stable cardiovascular disease. The first Phase 3 Trial, under agreement with the FDA on a Special Protocol Assessment, includes this patient population as well as two novel endpoints for approval of acute treatment of migraine. CoLucid has successfully completed seven clinical studies for lasmiditan, including a Phase 2b study treating a single migraine attack in 391 patients. Lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing (p<0.0001). Lasmiditan also achieved numerous secondary endpoints and was well tolerated at all doses. No evidence of drug-related cardiovascular adverse effects or chest symptoms has been reported. CoLucid was founded in 2005 by Pappas Ventures. The company's investors include Auriga Partners, Care Capital, Domain Associates, Novo Ventures, Pappas Ventures, Pearl Street Venture Funds, TVM Capital Life Science and Triathlon Medical Ventures.